NUCLIDIUM

Nuclidium is a clinical-stage biotechnology company developing copper-based radiopharmaceuticals for cancer diagnosis and treatment. The company utilizes a platform leveraging Copper-61 for diagnostics and Copper-67 for therapeutics to create theranostic solutions for diverse tumor indications. Their technology aims to improve diagnostic accuracy and treatment accessibility by using the same target molecules for both imaging and therapy.